Harri Sihto

Dr. Harri Sihto

University of Helsinki, Helsinki, Uusimaa, Finland
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2012 in JAMA
Verified
Journal Article
Open access
PDF file
HJHeikki Joensuu
Heikki Joensuu
MEMikael Eriksson
Mikael Eriksson
KHKirsten Sundby Hall
Kirsten Sundby Hall
JHJörg T. Hartmann
Jörg T. Hartmann
DPDaniel Pink
Daniel Pink
PRPeter Reichardt
Peter Reichardt
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Gastrointestinal stromal tumors are usually found in the stomach or the small intestine but can occur at any site along the gastrointestinal tract and rarely elsewhere within the abdominal cavity.1 The median age at presentation is 60 to 65 years, and the annual incidence approximately 10 cases per million.2-4 Most GISTs (75% to 80%) harbor an activating mutation in the KIT oncogene and 5% to 10% in platelet-derived growth factor receptor-α (PDGFRA), which are important for tumor molecular pathogenesis.5 The malignancy potential of GIST varies from negligible in micro GIST to aggressive cancer.6,7 Several stratification schemes are available for assessing the risk of recurrence when GIST has been resected with potential curative intent.1,2,8-10

1 July 2009 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
Harri SihtoHarri Sihto
Harri Sihto
HKHeli Kukko
Heli Kukko
VKVirve Koljonen
Virve Koljonen
RSRisto Sankila
Risto Sankila
TBTom Böhling
Tom Böhling
HJHeikki Joensuu
Heikki Joensuu
Background Merkel cell carcinoma is a rare malignancy of the skin. Integration of Merkel cell polyomavirus (MCPyV) DNA to the tumor genome is frequent in these cancers. The clinical consequences of MCPyV infection are unknown. Methods We analyzed formalin-fixed paraffin-embedded Merkel cell carcinoma tissue samples from 114 of 207 patients diagnosed with Merkel cell carcinoma in Finland from 1979 to 2004 for the presence of MCPyV DNA with the use of polymerase chain reaction (PCR), quantitative PCR, and DNA sequencing and examined associations between tumor MCPyV DNA status and histopathologic factors and survival. The median follow-up time after Merkel cell carcinoma diagnosis for subjects who were alive was 9.9 years (range = 4.9–21.9 years). All P values are two-sided. Results MCPyV DNA was present in 91 carcinomas (79.8%). Compared with MCPyV DNA–negative cancers, MCPyV DNA–positive cancers were more often located in a limb (40.7% vs 8.7%, P = .015) and less frequent in patients who had regional nodal metastases at diagnosis (6.6% vs 21.7%, P = .043). Patients with MCPyV DNA–positive tumors had better overall survival than those with MCPyV DNA–negative tumors (5-year survival: 45.0% vs 13.0%, respectively; P < .001, two-sided log-rank test). Conclusions MCPyV infection is associated with clinical outcomes in patients with Merkel cell carcinoma. These findings lend support to the hypothesis that viral infection is frequently associated with the pathogenesis of Merkel cell carcinoma.

1 September 2005 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
JAJohanna Andersson
Johanna Andersson
Harri SihtoHarri Sihto
Harri Sihto
JMJeanne M Meis-Kindblom
Jeanne M Meis-Kindblom
HJHeikki Joensuu
Heikki Joensuu
NNNina Nupponen
Nina Nupponen
LKLars-Gunnar Kindblom
Lars-Gunnar Kindblom
Gastrointestinal stromal tumors (GIST) have been reported to occasionally occur in patients with neurofibromatosis type 1 (NF1). This study aims to describe the phenotypic and genotypic characteristics of GIST in NF1 patients and attempts to elucidate the relationship between them. We analyzed GIST arising in 15 NF1 patients (8 males and 7 females, 19-82 years of age). Eleven patients had multiple GISTs (3 to >100 tumors) ranging from 1 mm to 10 cm in size and predominantly involving the small intestine including the duodenum. Tumors were symptomatic in 8 patients and incidental findings in the remaining 7 patients. Microscopically, the tumors cells were typically spindled and the mitotic rate low; 9 patients had tumors classified as very low or low risk and 6 as intermediate risk GIST. Nine patients were treated surgically and none developed metastases or died of disease. Immunohistochemical stains for CD117 were strongly positive in 47 of 50 GIST; they also accentuated hyperplastic foci (diffuse and focal) of the interstitial cells of Cajal that were often associated with microscopic GIST in the surrounding intestinal muscle wall. No KIT or PDGFRA mutations were detected in 24 GIST from 12 patients using dHPLC analysis and DNA sequencing. We conclude that patients with NF1 have a high risk of developing GIST. NF1-associated GIST are also phenotypically and genotypically distinct from sporadic GIST, indicating that different pathogenetic mechanisms are involved in their evolution.

13 September 2011 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
Harri SihtoHarri Sihto
Harri Sihto
JLJohan Lundin
Johan Lundin
MLMikael Lundin
Mikael Lundin
TLTiina Lehtimäki
Tiina Lehtimäki
ARAri Ristimäki
Ari Ristimäki
HJHeikki Joensuu
Heikki Joensuu
Introduction: Some molecular subtypes of breast cancer have preferential sites of distant relapse. The protein expression pattern of the primary tumor may influence the first distant metastasis site. Methods: We identified from the files of the Finnish Cancer Registry patients diagnosed with breast cancer in five geographical regions Finland in 1991-1992, reviewed the hospital case records, and collected primary tumor tissue. Out of the 2,032 cases identified, 234 developed distant metastases after a median follow-up time of 2.7 years and had the first metastatic site documented (a total of 321 sites). Primary tumor microarray (TMA) cores were analyzed for 17 proteins using immunohistochemistry and for erbB2 using chromogenic in situ hybridization, and their associations with the first metastasis site were examined. The cancers were classified into luminal A, luminal B, HER2+ enriched, basal-like or non-expressor subtypes. Results: A total of 3,886 TMA cores were analyzed. Luminal A cancers had a propensity to give rise first to bone metastases, HER2-enriched cancers to liver and lung metastases, and basal type cancers to liver and brain metastases. Primary tumors that gave first rise to bone metastases expressed frequently estrogen receptor (ER) and SNAI1 (SNAIL) and rarely COX2 and HER2, tumors with first metastases in the liver expressed infrequently SNAI1, those with lung metastases expressed frequently the epidermal growth factor receptor (EGFR), cytokeratin-5 (CK5) and HER2, and infrequently progesterone receptor (PgR), tumors with early skin metastases expressed infrequently E-cadherin, and breast tumors with first metastases in the brain expressed nestin, prominin-1 and CK5 and infrequently ER and PgR. Conclusions: Breast tumor biological subtypes have a tendency to give rise to first distant metastases at certain body sites. Several primary tumor proteins were associated with homing of breast cancer cells.

20 January 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HJHeikki Joensuu
Heikki Joensuu
MEMikael Eriksson
Mikael Eriksson
KHKirsten Sundby Hall
Kirsten Sundby Hall
ARAnnette Reichardt
Annette Reichardt
JHJörg T. Hartmann
Jörg T. Hartmann
PRPeter Reichardt
Peter Reichardt
Purpose: Three years of adjuvant imatinib therapy are recommended for patients with GI stromal tumor (GIST) with high-risk features, according to survival findings in the Scandinavian Sarcoma Group XVIII/AIO (Arbeitsgemeinschaft Internistische Onkologie) trial. To investigate whether the survival benefits have persisted, we performed the second planned analysis of the trial. Patients and Methods: Eligible patients had macroscopically completely excised, KIT-positive GIST with a high risk of recurrence, as determined by using the modified National Institutes of Health criteria. After surgery, the patients were randomly assigned to receive imatinib for either 1 or 3 years. The primary objective was recurrence-free survival (RFS), and the secondary objectives included survival. Results: A total of 400 patients were entered onto this open-label study between February 4, 2004, and September 29, 2008. During a median follow-up of 90 months, 171 recurrences and 69 deaths were detected. Patients assigned to the 3-year group had longer RFS than those assigned to the 1- year group; 5-year RFS was 71.1% versus 52.3%, respectively (hazard ratio [HR], 0.60; 95% CI 0.44 to 0.81; P < .001), and survival was 91.9% versus 85.3% (HR, 0.60; 95% CI, 0.37 to 0.97; P = .036). Patients in the 3-year group survived longer in the subset with centrally confirmed GIST and without macroscopic metastases at study entry (93.4% v 86.8%; HR, 0.53; 95% CI, 0.30 to 0.93; P = .024). Similar numbers of cardiac events and second cancers were recorded in the groups. Conclusion: Three years of adjuvant imatinib therapy results in longer survival than 1 year of imatinib. High 5-year survival rates are achievable in patient populations with high-risk GIST.

1 May 2006 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
JAJohanna Andersson
Johanna Andersson
PBPer Bümming
Per Bümming
JMJeanne M. Meis–Kindblom
Jeanne M. Meis–Kindblom
Harri SihtoHarri Sihto
Harri Sihto
NNNina Nupponen
Nina Nupponen
BNBengt Nilsson
Bengt Nilsson